An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes

ABSTRACT

Introduction: Accumulating data from recent studies has altered the gold standard of care for diabetes treatment. In patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or those at high risk for CVD, subsequently to lifestyle changes and metformin therapy, the administration of an SGLT-2 inhibitor with established benefits for cardiovascular outcome (CVOT) should be considered.

Areas covered: Tofogliflozin is the most selective SGLT-2 inhibitor and has been approved for the treatment of T2D in Japan. This review summarizes the available data on Tofogliflozin as compared to other SGLT-2 inhibitors, and primarily the three SGLT-2 inhibitors with published CVOT: Empagliflozin, Canagliflozin and Dapagliflozin.

Expert opinion: Tofogliflozin’s higher selectivity profile increases the positive effects on cardiovascular (CV) outcomes and death and reduces side effects. However, the clinical data on Tofogliflozin from both clinical and real-world studies remain sparse and much less abundant than the other main 3 SGLT-2 inhibitors, thus calling for caution and underscoring the need for further research.

KEYWORDS:

• Type 2 diabetes
• SGLT-2 inhibitors
• Tofogliflozin
• cardiovascular outcome
• safety and efficacy

Box 1. Drug summary box

Declaration of interest

Genya Aharon-Hananel is employed by the Diabetes Medical Center, Tel Aviv (the owner of which being the distributor of Freestyle Libre in Israel). Dr Aharon-Hananel is also on Speakers Bureaus for Novo Nordisk and Sanofi. Itamar Raz has served on the advisory boards of AstraZeneca, Boehringer Ingelheim, Concenter BioPharma/Silkim Ltd, Eli Lilly and Company, Merck Sharp & Dohme, Novo Nordisk, Orgenesis, Pfizer Inc, Sanofi, SmartZyme Innovation Ltd and Panaxia as well as having acted and/or acts as a consultant for AstraZeneca/Bristol-Myers Squibb, FuturRx Ltd, Insuline Medical, Medial EarlySign Ltd, CamerEyes, Exscopia and Dermal Biomics Inc. Dr Raz has also served on Speaker’s Bureaus for AstraZeneca/Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, Merck Sharp & Dohme, Novartis Pharma AG, Novo Nordisk, Inc and Teva. Dr Raz is also a Stock/Shareholder of Glucome Ltd, Insuline Medical, Orgenesis, DarioHealth and CamerEyes and is an employee also of the Diabetes Medical Center, Tel Aviv. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This manuscript was not funded.